Impax Laboratories, Inc.
IPXL
NASDAQ18.30
USD
+0.10
- -
CIK
0001003642
Return %
Stock
S&P500
1Y
- -
26.57
3Y
- -
76.60
5Y
- -
78.48
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Address
- CA United States of America
- IPO Date
- Dec 19, 1995
- CIK
- 0001003642
- Website
- impaxlabs.com
- Similar Companies
- Business
- Impax Laboratories, Inc. is a specialty pharmaceutical company focused on the development, manufacture, and marketing of controlled-release and multi-source generic pharmaceutical products. The company’s core product portfolio includes proprietary and generic oral solid dosage pharmaceuticals, controlled-release formulations, and alternative dosage forms. Impax produces and markets products for central nervous system disorders, oncology, and other therapeutic categories, serving patients primarily in the United States. Founded in 1999 and headquartered in Hayward, California, the company operates multiple manufacturing and development sites across the United States. In terms of recent major changes, Impax Laboratories completed a business combination with Amneal Pharmaceuticals in 2018, resulting in the company operating under the Amneal Pharmaceuticals umbrella. This strategic consolidation expanded their product portfolio and pipeline across generic and specialty pharmaceutical segments, improved manufacturing capabilities, and enhanced cost efficiencies. The combined company continues to focus on delivering growth through high-value generic products, branded franchises, and complementary drug delivery technologies. The integration has positioned the company as a leading player in both U.S. generic pharmaceuticals and specialty drugs markets. Beyond generic and specialty products, Impax has developed controlled-release drug delivery technologies that improve patient compliance and therapeutic outcomes, with multiple FDA approvals and pending applications. The company targets healthcare providers and patients with a broad geographic reach primarily within the U.S. pharmaceutical market. Impax Laboratories also forms strategic alliances and partnerships to develop and commercialize novel dosage forms and branded therapies. These efforts align with their strategic focus on expanding product offerings and market access in specialty pharmaceutical segments. In summary, Impax Laboratories, Inc. operates as a diversified specialty pharma company offering generic and proprietary controlled-release products, including multi-source oral solids for CNS and other indications. Its transformation through the Amneal combination and continued expansion of drug delivery technologies exemplify its commitment to innovation and market leadership in the pharmaceutical industry. The company maintains a strong presence in the U.S. market with manufacturing and R&D operations supporting growth in generics and specialty branded pharmaceuticals.